Company / Operating Cash Flow
Viking Therapeutics, Inc. Operating Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$278.7M
FY2025
5-year range
-$278.7M / -$21.8M
FY2021-FY2025
Trend
-217.4%
vs FY2024
Sector context
#189 of 216
Health Care
What the data says
Operating Cash Flow changed -217% YoY in FY2025, a notable deviation from the 9-year average annual change of -60%.
Based on SEC 10-K filings.
-$279M in FY2025.
Declined from -$48M to -$279M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 13% in Health CareTop 87% of 216This company -$278.7M Sector average $658.7M
▼
-142.3% below sector average
Key checks
Key Insights
- In FY2025, operating cash flow decreased 217.4% year-over-year.
- Ranks #189 out of 216 companies in the Health Care sector.
- Peak operating cash flow was recorded in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$278.7M | -217.4% |
| FY2024 | -$87.8M | -84.5% |
| FY2023 | -$47.6M | +0.0% |
| FY2022 | -$47.6M | -118.5% |
| FY2021 | -$21.8M | +12.0% |
| FY2020 | -$24.8M | -32.0% |
| FY2019 | -$18.8M | -27.1% |
| FY2018 | -$14.8M | +0.0% |
| FY2017 | -$14.8M | -69.0% |
| FY2016 | -$8.7M | -448.7% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026